Top Story Today
The Only Drug on Earth That Kills Cancer by Destroying Its Telomeres Just Cleared a Major Phase 3 Hurdle
MAIA Biotechnology says its Phase 3 trial of ateganosine shows a high probability of technical success at both interim and final analyses. The drug works unlike anything else in oncology: it hijacks telomerase, the enzyme cancer cells use to replicate forever, and weaponizes it to shred the cell's own telomeric DNA. That damage doesn't just kill tumor cells directly, it also triggers the immune system's cGAS/STING pathway, essentially turning dying cancer cells into a distress beacon for T cells. The target population is roughly 50,000 U.S. patients a year facing third-line lung cancer treatment where no standard of care exists. FDA Fast Track designation could put a regulatory decision within 12 to 18 months.
Why it matters: If ateganosine works, it opens an entirely new therapeutic category in a $50 billion immunotherapy market by going after the machinery of cancer cell immortality rather than competing in the crowded checkpoint inhibitor lane, and it does so in a patient population that currently has nowhere to turn.
Read more →Funding and Financings
$197M Says the GLP-1 Duopoly Might Have a Blind Spot
Alveus Therapeutics closed a $197 million Series A to develop obesity drugs that skip the GLP-1 playbook entirely. Its lead differentiated asset is ALV-200, a selective agonist of amylin receptor 3, a satiety hormone most drug developers have ignored. Even more telling: Novo Holdings, the investment arm of the company that dominates obesity treatment, participated in the round. When the market leader hedges its own position, it tells you the current approach might have a ceiling.
Read more →Clinical and Regulatory
A Parkinson's Drug Just Got the Regulatory Shortcut Most Biotechs Can Only Dream About
Serina Therapeutics dosed its first patient in a Phase 1b registrational trial of SER-252 for advanced Parkinson's disease. The FDA agreed to a 505(b)(2) pathway, a streamlined approval route that skips the usual multi-phase gauntlet. The trial targets patients whose symptoms remain uncontrolled despite standard treatment, with an initial safety readout expected by Q3 2026.
Read more →The Third Non-Covalent BTK Inhibitor Just Entered Phase 3, and It's Gunning for a Different Tumor
Hutchmed is taking HMPL-760 into a Phase 3 trial for relapsed diffuse large B-cell lymphoma, making it the third non-covalent BTK inhibitor to reach late-stage development after Lilly's Jaypirca and Merck's nemtabrutinib. Non-covalent inhibitors work against the resistance mutation that renders older BTK drugs useless. The trial is China-exclusive, reflecting a growing trend of running pivotal cancer trials where enrollment is faster and patient pools are deep.
Read more →Approvals and Regulatory Milestones
The UK Just Approved a Breast Cancer Drug That Doesn't Block Estrogen Receptors. It Destroys Them.
The MHRA approved imlunestrant, an oral estrogen receptor degrader, for ER-positive, HER2-negative metastatic breast cancer patients with ESR1 mutations. Unlike older hormonal therapies that merely block the estrogen receptor, imlunestrant tags it for complete destruction via the cell's own protein recycling system. ESR1 mutations drive resistance in roughly 20 to 30 percent of advanced ER-positive breast cancers, giving this approval a clear precision oncology angle that could reshape treatment sequencing.
Read more →